Efficacy and safety of Dingluo nasal drops(丁萝滴鼻剂)for the acute treatment of migraine:a pilot randomized trial
摘要
OBJECTIVE:To evaluate the efficacy and safety of two doses of Dingluo nasal drops(丁萝滴鼻剂)compared to placebo in the acute treatment of migraine.
METHODS:This randomized,parallel-treatment,placebo-controlled,double-blind trial was conducted at Dongzhimen hospital,Beijing University of Chinese Medicine.Eligible participants were randomly assigned(1∶1∶1)to receive either full-dose Dingluo nasal drops,half-dose Dingluo nasal drops,or a placebo for three migraine attacks.The primary endpoint was the proportion of participants achieving pain freedom at 2 h postdose,assessed in all randomly assigned participants who received study medication.
RESULTS:A total of 91 participants with 257 attacks were included in the statistical analysis.At 2 h postdose,Dingluo nasal drops were superior to placebo for freedom from pain[high dose vs placebo:14.61%vs 1.20%,P=0.001,risk difference 13.40,95%CI(5.70,21.11);low dose vs placebo:17.65%vs 1.20%,P<0.001,risk difference:16.44,95%CI(8.00,24.88)].The high dose and the low dose effected similarly for freedom from pain[14.61%vs 17.65%,P=0.585,risk difference:-3.04,95%CI(-13.97,7.89)].It showed a good efficacy in pain relief.The most common adverse events were nasal burning and nasal itchiness.All adverse events are transient and dissipate within a relatively short time frame.
CONCLUSIONS:Dingluo nasal drops demonstrated superior efficacy to placebo in achieving pain freedom for acute migraine treatment.Mild nasal reactions were observed,with a trend toward reduced discomfort at the half-dose concentration.